News
TRVN
1.580
-5.95%
-0.100
BRIEF-Trevena Enrolls First Subject In Trv045 Proof-Of-Concept Trial
Reuters · 01/09 13:36
Trevena Enrolls First Subject In TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism Of Action And Target Engagement
Benzinga · 01/09 12:39
"Trevena Has Received A Notice Of Allowance For Its U.S. Patent Application 16/613,152 Titled 'Compounds For Modulating S1p1 Activity And Methods Of Using The Same (For The Treatment Of Pain)'" - USPTO
Benzinga · 01/04 18:06
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual Meeting OLINVYK poster presentation on reduced effect on neurocognitive function in humans compared ...
GlobeNewswire · 12/08/2022 12:00
BRIEF-Trevena Regains Compliance With Nasdaq Listing Requirements
Reuters · 11/29/2022 12:23
Trevena Regains Listing Compliance with Nasdaq Stock Market
Trevena Regains Listing Compliance with Nasdaq Stock Market
MT Newswires · 11/29/2022 08:12
InMed, AirSculpt top healthcare gainers; BrainsWay, Brookdale among losers
Seekingalpha · 11/16/2022 15:01
Trevena launches $8M securities offering
Seekingalpha · 11/16/2022 13:09
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/16/2022 13:08
Trevena, Inc. Announces $8M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Benzinga · 11/16/2022 13:01
Trevena Launches $8 Million Registered Direct Stock Offering; Shares Fall
Trevena Launches $8 Million Registered Direct Stock Offering; Shares Fall
MT Newswires · 11/16/2022 10:33
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session
Benzinga · 11/10/2022 18:05
Cano Health, Vacasa, Organogenesis, And Some Other Big Stocks Moving Lower On Thursday
Benzinga · 11/10/2022 15:50
BRIEF-Trevena Announces Reverse Stock Split
Reuters · 11/09/2022 22:00
Trevena slides 18% after the bell on 1-for-25 reverse stock split
Seekingalpha · 11/09/2022 21:17
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 11/09/2022 18:44
Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates
Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/09/2022 13:25
Trevena Q3 EPS $(0.09) Misses $(0.08) Estimate. Posted Negative Revenue Of $438K. Cash Balance Of $40.4M Funds Operations into Q3 2023
Benzinga · 11/09/2022 12:04
Trevena GAAP EPS of -$0.09 in-line, revenue of -$0.44M misses by $0.88M
Seekingalpha · 11/09/2022 12:04
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator
TRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia Nonclinical study showed anti-inflammatory signaling, suggesting a potential disease-modifying effect of TRV045 in the treatment of epilepsy, based on astrocyte c...
GlobeNewswire · 11/09/2022 12:02
More
Webull provides a variety of real-time TRVN stock news. You can receive the latest news about Trevena Inc through multiple platforms. This information may help you make smarter investment decisions.
About TRVN
Trevena Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients affected by central nervous system (CNS) disorders. It is developing OLINVYK, a G-protein biased MOR ligand for acute pain in adults. It is developing TRV027, an angiotensin II type 1 (AT1), receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome (ARDS), and abnormal blood clotting in patients with COVID-19. It is developing TRV250, a G-protein biased delta-opioid receptor (DOR), is developed for the treatment of acute migraine. The Company is focused on exploring other formulations, such as transmucosal or transdermal administration for breakthrough or chronic pain, respectively. The Company is in the Phase III clinical program for OLINVO with the enrollment of patients in the ATHENA study, a Phase III, open-label, multicenter study.